Participating Companies

CureVac AG [CVAC] US$7,795 MM MCap
Cure­vac is a pri­vate Ger­man com­pany with mR­NA plat­form, di­ver­si­fied pipe­line, and three lead pro­grams in ph1: CV8102 (vari­ous can­cer in­di­ca­tions), CV9202 (NS­CLC) and CV7202 (Ra­bies). Last fi­nanc­ing round done at over $1bn. Other com­pa­nies in the space: MR­NA, TBIO, BN­TX. [more in­for­ma­tion]
Deutsche Bank AG [DB] US$16,681 MM MCap
Deutsche Bank’s ADR team is part of the Trust & Agen­cy Ser­vices busi­ness within the new­ly cre­at­ed Cor­po­rate Bank Di­vi­sion. Deutsche Bank was ap­point­ed as DR Bank for the largest Life Sci­ences sec­tor ADR IPO of 2019 with the $582m Nas­daq list­ing of Genmab A/S, con­firm­ing our po­si­tion as the lead­ing is­suer of cap­i­tal in the US ADR mar­kets. [more in­for­ma­tion]
Ernst & Young
[more in­for­ma­tion]
Goldman Sachs & Co.
Gold­man Sachs & Co. (U.S.) is a full-ser­vice glob­al in­vest­ment bank that of­fers equi­ty and fixed in­come re­search ser­vices to in­sti­tu­tio­n­al in­ves­tors. The firm is head­quar­tered in New York and main­tains of­fices in 23 coun­tries world­wide and was found­ed in 1829. [more in­for­ma­tion]
Goodwin Procter LLP
More than 1,000 cor­po­rate and liti­ga­tion at­tor­neys lev­er­age their spe­cif­ic ex­pe­ri­ence and as­sem­ble full-ser­vice teams to ad­vise clients in th­ese and ad­ja­cent in­dus­tries. [more in­for­ma­tion]
Immatics NV [IMTX] US$583 MM MCap
Im­mat­ics com­bines the dis­cov­ery of true tar­gets for can­cer im­munother­a­pies with the de­vel­op­ment of the right T cell re­cep­tors with the goal of en­abling a ro­bust and spe­cif­ic T cell re­sponse against th­ese tar­gets. We are com­mitt­ed to de­liv­er­ing the pow­er of T cells and to un­lock­ing new av­enues for pa­tients in their fight against can­cer. [more in­for­ma­tion]
Jefferies LLC [JEF] US$4,551 MM MCap
In late 2002, Jef­feries & Com­pany (U.S. The firm was found­ed in 1962 by Boyd Jef­feries and is head­quar­tered in New York and has of­fices world­wide. Leu­ca­dia Na­tio­n­al Cor­po­ra­tion ac­quired Jef­feries Group, LLC on March 1, 2013, on­the same day Jef­feries & Com­pany (U.S. [more in­for­ma­tion]
[more in­for­ma­tion]
Solebury Trout
With al­most two de­cades of ex­pe­ri­ence in the biotech­nol­o­gy, phar­ma­ceu­ti­cal, med­i­cal tech­nol­o­gy and life sci­ence tech­nol­o­gy sec­tors, the Trout Group of­fers its clients the knowl­edge base need­ed to clar­i­fy in­vest­ment themes and lev­er­age key re­la­tion­ships for in­creased ex­po­sure to the prop­er au­di­ence. [more in­for­ma­tion]
SVB Leerink
SVP Leerink is a full-ser­vice in­vest­ment bank that of­fers equi­ty re­search ser­vices to in­sti­tu­tio­n­al and re­tail in­ves­tors. The firm al­so of­fers in­sti­tu­tio­n­al sales/trad­ing, cor­po­rate fi­nance, and as­set ma­n­age­ment ser­vices. Leerink Part­n­ers, LLC al­so us­es anal­y­sis from ME­DA­Corp, a pri­vate­ly held com­pany that pro­vides biomed­i­cal con­sult­ing ser­vices. [more in­for­ma­tion]